RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections


Motsch J., de Oliveira C. M. , Stus V., Koksal I., Lyulko O., Boucher H. W. , ...More

CLINICAL INFECTIOUS DISEASES, vol.70, no.9, pp.1799-1808, 2020 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 70 Issue: 9
  • Publication Date: 2020
  • Doi Number: 10.1093/cid/ciz530
  • Journal Name: CLINICAL INFECTIOUS DISEASES
  • Journal Indexes: Science Citation Index Expanded
  • Page Numbers: pp.1799-1808
  • Keywords: carbapenem resistant, KPC, nosocomial pneumonia, cIAI, cUTI, DISEASES SOCIETY, CLINICAL-PRACTICE, GUIDELINES, ASSOCIATION, RELEBACTAM, MANAGEMENT, MEROPENEM, AMERICA, PHASE-2, ADULTS

Abstract

Background: The beta-lactamase inhibitor relebactam can restore imipenem activity against imipenem-nonsusceptible gram-negative pathogens. We evaluated imipenem/relebactam for treating imipenem-nonsusceptible infections.